The objective was to assess persistence with antihypertensive therapy (AHT) and discontinuation patterns in patients newly dispensed different antihypertensive drug classes in a natural Canadian population-based setting. Hypertensive patients initiating AHT monotherapy were included in this 3-year retrospective cohort study (N ¼ 21 326) using the Saskatchewan health-care databases. Persistence was defined as consistently refilling a new prescription for AHT within 90 days of a previous dispensing. New courses of AHT were also documented in nonpersistent patients. Kaplan-Meier and Cox regression analyses were used to compare persistence and new courses of therapy across initial drugs. Compared to the newer angiotensin II antagonists (AIIAs), the likelihood of discontinuing therapy over the 39-month study period was significantly higher for angiotensin-converting enzymes inhibitors (HR ¼ 1.29; 95% CI ¼ 1.16-1.43), calcium channel blockers (HR ¼ 1.42; 95% CI ¼ 1.27-1.60), beta blockers (HR ¼ 1.62; 95% CI ¼ 1.45-1.80) and diuretics (HR ¼ 1.92; 95% CI ¼ 1.73-2.14). In the year following treatment discontinuation, between 54 and 75% of patients initiated a second course of treatment. Patients initiated on an AIIA had a significantly higher likelihood of starting a new course of therapy after a first treatment discontinuation, compared to all other agents. In conclusion, hypertensive patients initiated on an AIIA not only had greater persistence to AHT but were also more likely to initiate a new course of AHT after discontinuation than those initiating treatment with other agents. Further studies are required that relate intermittent treatment behaviours to health outcomes and costs in hypertension.
Introduction
Hypertension, defined as systolic blood pressure higher than 140 mmHg and/or diastolic pressure higher than 90 mmHg, is a key factor in the onset of cardiovascular disease (CVD), the leading cause of death in North America. 1, 2 Hypertension is a major health problem affecting more than 20% of the Canadian population. 3 The 1999 total cost of treating hypertension in the US was estimated to be $33.3 billion: 4 direct costs of medical care included $8.1 billion for drugs, $7.1 billion for hospital and nursing home care, $1.5 billion for home health care and other medical requirements, and $8.8 billion for lost productivity resulting from hypertension-related morbidity and mortality. 4 The 2004 Canadian recommendations for the management of hypertension, 5 the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 2 and the International Society of Hypertension Guidelines for the Management of Hypertension 6 are examples of attempts to address the need for continued improvement in the management of hypertension. However, there is ample evidence for poor control of hypertension in many populations. For instance, it has been estimated that in Canada, only 16% of hypertensive patients are controlled, 23% are treated but not controlled, 19% are not treated and 42% are unaware of their condition. 7 In the US, it has been estimated that only 34% of hypertensive patients are controlled, 41% are not treated and 30% are unaware of their condition. 2 A lack of adherence to antihypertensive (AHT) therapy is considered to contribute to the inappropriate control of hypertension for the majority of hypertensive patients. 2 The association of lack of blood pressure control to cardiovascular risk and premature death has been widely documented. The usefulness of treating high blood pressure in preventing long-term events such as myocardial infarctions and stroke has been clearly established. [8] [9] [10] Adherence to recommended drug regimens is a major contributor to adequate blood pressure control. A typology that differentiates different components of treatment adherence was proposed in 2001 by Urquhart. 11 In his view, the first component of adherence to therapy is acceptance, defined as the initial agreement by the patient with the proposed treatment. Acceptance may be operationalized by filling a first prescription and obtaining a first refill. Persistence with therapy is a second component of treatment adherence. Persistence may be defined as continuously refilling prescriptions in accordance with the suggested duration of therapy. Finally, compliance refers to the patient taking the drug as directed, with regards to the prescribed dosage, schedule and method of ingestion. These three components are known to be important elements in determining the success of any therapy. 2 Persistence is a primary factor in determining the success of long-term therapy, which is of particular relevance in the treatment of hypertension given that this condition is asymptomatic, chronic and typically requires long-term commitment to pharmacotherapeutic regimens in order to gain and maintain cardiovascular protection. In addition to hindering disease control, lack of persistence with therapy may entail substantial health-care resources. [12] [13] Numerous studies have examined treatment persistence in hypertension. Some of these predated the introduction of newer drug classes such as the angiotensin II antagonists (AIIAs). [14] [15] [16] [17] [18] [19] More recent studies have included AIIAs, most of which had a duration of follow-up of no more than 1 year, [20] [21] [22] or have limited their interest to persistence with the initial antihypertensive medication. [23] [24] [25] None of these studies have examined persistence and discontinuation patterns longitudinally, including new courses of therapy after treatment interruptions.
Using a defined group of hypertensive patients selected from the Saskatchewan Health databases who were prescribed pharmacotherapy from one of the five major AHT drug classes (AIIAs, angiotensinconverting enzymes inhibitors (ACEIs), calcium channel blockers (CCBs), beta blockers (BBs) or diuretics) for the first time, our study sought to examine persistence and discontinuation patterns across AHT drug classes in a natural clinical setting.
Materials and methods

Study subjects
A retrospective cohort study utilizing the universal health insurance databases managed by Saskatchewan Health was performed. These electronic health databases include information on patient demographics, prescription drugs and hospital and physician services pertaining to most residents of the province of Saskatchewan (population approximately 1 million). Individuals not covered by Saskatchewan Health include those with federally funded health care such as members of the Royal Canadian Mounted Police, Canadian Forces and Registered Indians, who totally represent around 7% of the population). 26, 27 Eligible for cohort entry were subjects with a diagnosis of hypertension (International Classification of Diseases-9 codes 401-404) 28 recorded in the physician services or hospital separation files between January 1, 1994 and September 30, 1999; aged 18-80 years; newly dispensed AHT between January 1, 1997 and September 30, 1999 (no AHT prescription 12 months prior to the first dispensing date, labelled here as treatment initiation); and initiating therapy with one of the five major antihypertensive drug classes, that is, AIIAs, ACEIs, BBs, CCBs or diuretics. Patients dispensed more than one agent at treatment initiation were excluded due to the difficulty arising in disentangling combination therapies to stockpiling. Those represented 8% of the total cohort.
Study subjects were followed from treatment initiation up to March 31, 2000 or death, whichever came first, and treatment gaps documented, as depicted in Figure 1a .
Persistence analysis
Persistence with therapy was defined as continuously refilling a prescription for any antihypertensive drug within 90 days of previous dispensing (assumed to last 15-30 days), regardless of switches across drug classes and add-on therapies. The 2-month cutoff point for drug holiday was based on the ground that with an arbitrary 80% threshold for compliance, 2.5 months without AHT would be required for a patient to be considered not compliant enough to benefit from therapy in a 1-year period. Hospital-days were excluded from the 90 days without refill requirement for treatment discontinuation as no information is available on drug use during hospital stays. Discontinuation date was defined as the date of the last prescription not refilled, to which was added 90 days. For nonpersistent patients, a new course of therapy was allowed which was defined as treatment initiation with any AHT following a first 90-day period without prescription filling. Time to a first treatment discontinuation (days from treatment initiation to discontinuation) and time to a first new course of therapy after initial treatment discontinuation (days from first discontinuation to new course of therapy) were computed and described by subcohorts, as defined by initial AHT. Patients were censored at study termination date if they were persistent with therapy throughout follow-up, or at time of death if applicable. Persistence was evaluated for up to a 39-month period from the index date. For illustrative purposes, Figure 1b displays antihypertensive drug use in a hypothetical patient considered to have discontinued therapy after 215 days (first 90-day period without prescriptions, excluding hospitaldays, ends at day 215) and started a new course of therapy after 275 days.
Statistical analysis
Patients' characteristics at treatment initiation were described and significance tests performed using w 2 -tests for proportions and analyses of variance for continuous variables. Persistence data for each AHT subcohort were analysed longitudinally using the Kaplan-Meier method. Statistical significance of the differences between curves was assessed using the log-rank test. Cox regression analyses were conducted to compare the likelihood of treatment discontinuation for each AHT subcohort compared to AIIAs over the 39-month study period, controlling for age, gender, and year of cohort entry, therefore allowing the proportion of subjects still on AHT therapy at different points in time to be compared across initial treatment groups. The likelihood of starting a new course of therapy after treatment discontinuation was also compared across initial treatment groups using Cox regression models. All the statistical analyses were performed using SAS for Windows, version 8.2.
Results
A total of 21 326 hypertensive patients initiated on AHT drug monotherapy were included in this study. Characteristics of the study population are shown in Table 1 . Patients initiated on diuretics and CCBs were slightly older than those initiated on AIIAs, ACEIs and BBs (overall Po0.0001). Also, patients initiated on a diuretic were less likely to be males (overall Po0.0001). Patients initiated on ACEIs, CCBs, BBs and diuretics entered the cohort earlier and had longer observation times than those initiated on an AIIA (overall Po0.0001), as expected due to the latter having been introduced on the market later on in time.
The cumulative persistence of patients for each AHT subcohorts over 39 months is shown in Figure 2 . The Kaplan-Meier survival curves, which take varying observation times into account, indicate that a higher proportion of patients initiated on an AIIA were persistent throughout the period of follow-up with 53% still on therapy after 3 years, compared to 40% for ACEIs, 38% for CCBs, 34% for BBs and 29% for diuretics. Persistence rates were significantly different between AIIAs and any other antihypertensive drug classes throughout the period of observation (overall Po0.0001). Table 2 shows the results of the Cox proportional hazard model covering the 39-month study period, after controlling for age, gender and year of cohort entry. Compared to the AIIA subgroup, the likelihood of discontinuing therapy was significantly higher for all the other drug classes, with adjusted hazard ratios for treatment discontinuation ranging from 1.29 for ACEIs (95% CI ¼ 1.16-1.43) to 1.92 for diuretics (95% CI ¼ 1.73-2.14). Table 2 Persistence and discontinuation of AHT C Bourgault et al second course of treatment is higher for patients initiated on an AIIA, followed by those initiated on an ACEI. At 1 year following initial treatment discontinuation, 75% of patients initially on an AIIA had started back on therapy, compared to 71% of ACEI users and 54-62% for CCB, BB and diuretic users.
Discussion
The present study indicates that hypertensive patients initiated on an AIIA showed significantly better persistence with AHT in the first 3 years than those initiated on other drug classes. There were also significant differences between drug classes in initiating a new course of therapy following discontinuation, with a 15-38% lower likelihood of doing so among patients initiated with ACEIs, CCBs, BBs or diuretics, compared to the AIIAs. Previous retrospective studies have also reported significant variations in persistence with AHT across drug classes. A Canadian study published in 1999 for instance 18 reported persistence rates after 12 months of 83% for ACEIs, 81% for CCBs, 78% for BBs and 74% for diuretics. A US study by Bloom 20 utilizing a large pharmaceutical benefits management organization database reported significantly greater persistence for the AIIAs (64%) compared to ACEIs (58%), CCBs (50%), BBs (43%), and thiazide diuretics (38%), at the 12-month follow-up. Conlin, 25 investigating a subgroup of Bloom's cohort, reported greater persistence at 48 months for patients who initiated therapy with AIIAs (51%) compared to ACEIs (47%), CCBs (41%), BBs (35%) and thiazide diuretics (16%). Other researchers have also reported a greater persistence at 18 23 and 36 months 29 for the AIIAs compared to any of the other antihypertensive classes. Our results are consistent with this evidence, suggesting that the class differentiation favouring the AIIAs subsists as long as 3 years after initiation of therapy.
Differences in absolute values between studies may be explained by variations in the length of observation and populations investigated, as well as by differences in methodology, especially in the use of different operational definitions for persistence. Persistence is intimately related to compliance with therapy. Indeed, persistence is a necessary condition for compliance, the latter being considered a quantitative measure of drug use in patients persisting with therapy. Unfortunately, studies abound that seem to confound to two related but different concepts. A number of studies 18, 20, 21, 23, 25 have indeed defined persistence according to whether or not the patient was still on therapy at a defined time point, for example, 12 months after starting therapy, without considering treatment patterns Persistence and discontinuation of AHT C Bourgault et al prior to that time point. Hence, a patient may have started therapy, stopped for a few months or even years and then started back, a behaviour that would not be captured by this cross-sectional measure and hence, would not meet our definition of persistence. Our study is original in that we have looked at persistence as a continuous phenomenon. To be persistent, one has to be 'exposed' to AHT on a continuous way, with a given (a priori defined) degree of compliance. The reasons why patients do not persist in taking their AHT, and why persistence rates differ across drug classes is not well understood. Differences in drug tolerability, dosing frequency, patient beliefs and health behaviours, and the nature of the patient-provider interaction, are factors that might also contribute to the varying persistence rates associated with AHT drug classes. 30 A recent Canadian study has shown that the risk of discontinuing a new course of AHT drug therapy is significantly associated with perceived side effects. 24 Yet, patients on AIIAs tend to perceive fewer side effects than those on ACEIs or CCBs. 31 A lack of drug insurance coverage, 24 younger age, 17, 20, 29 and gender 29 have also been shown to be associated with the risk of discontinuing therapy.
Another important finding emerges from this study. A high proportion of patients discontinuing treatment are returning on therapy within 1 year. Whereas studies suggest that a high proportion of patients are discontinuing therapy in the first 12 months, our results suggest that as much as 60% of those who discontinue are returning on treatment in the 12 months following discontinuation, which is consistent with an earlier study. 19 Moreover, not only does persistence with AHT vary across drug classes but the rate of starting a new course of therapy after stopping for some time is also greater for the newer AIIAs. Although patients discontinuing therapy may suffer from a lack of exposure to appropriate AHT during the period they are off therapy, this result suggests that there are opportunities to support patients soon after treatment initiation in better persisting with therapy in the light of better cardiovascular protection. As previously pointed out, further research is needed to better understand the clinical and economical consequences of varying patterns of antihypertensive drug use and intermittent treatment behaviours. 19 Persistence with AHT drugs in routine clinical practice is an important element in successful management of the hypertensive patient, especially since hypertension is an asymptomatic chronic condition that requires regular and long-term treatment. Persistence with AHT drug treatment impacts clinical outcomes for the patient as continuous drug treatment decreases the rates of mortality and morbidity associated with hypertension. [8] [9] [10] Indeed, reduction of cardiovascular risk will only be Persistence and discontinuation of AHT C Bourgault et al attained if AHT is maintained. Poor persistence associated with certain AHT drug classes is likely to be contributing to the generally poor control of blood pressure observed in Canada and the US, 2, 3 which not only has clinical consequences but also has economic implications. 4, 32 Poorly controlled hypertension and noncompliance are reportedly associated with extra utilization of health-care resources and increased costs. 4, [33] [34] [35] Switching and discontinuation have also been shown to increase the costs of hypertension. 32, 34, 36, 37 Our study constitutes a 'real world' insight into persistence and utilization of health-care resources in a population-based clinical hypertension cohort. Nonetheless, results should be considered in light of the study limitations. Analyses compared groups of patients defined by their initial AHT and switches across drug classes were not considered. Reasons for persistence, switching or discontinuation with the initial AHT drug class and data on blood pressure levels are not captured in the Saskatchewan Health databases, which precluded us to document their association with persistence. Treatment duration, which is of primordial importance in measuring persistence, had to be estimated using average figures. Like many others, this study was based on an analysis of refill patterns, yet refilling may not exactly represent actual use of an AHT drug, although evidence does suggest the contrary. 38, 39 Finally, other potential confounding factors such as comorbidity and risk factors for heart disease were not controlled for, and the effect of these variables on persistence and discontinuation could not be documented. Despite such limitations, the Saskatchewan Health databases are a worldrenowned resource for medical information data on a large population, are commonly used in health research, and validation checks of the data are a quality control feature of the databases. 26, 27 In conclusion, the results reported here suggest that the initial antihypertensive drug class is associated with different persistence or treatment discontinuation rates, which potentially lead to varying utilization of limited health-care resources. It is unclear why in comparison to the other AHT drug classes, AIIAs were associated with greatest persistence to AHT and better chance to start a new course of AHT after discontinuing. Further investigation is needed to explore the relationship between persistence and discontinuation patterns, and the utilization of health-care resources in this and other populations and settings.
